Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04013880
Recruitment Status : Withdrawn (Loss of funding)
First Posted : July 10, 2019
Last Update Posted : July 7, 2020
Sponsor:
Collaborators:
Astex Pharmaceuticals, Inc.
Forma Therapeutics, Inc.
Information provided by (Responsible Party):
Paul Ferrell, Vanderbilt-Ingram Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2022